Higher Red Meat Intake Tied to Worse Imaging Measures of CV Health
Adverse ventricular remodeling, poorer cardiac function, and higher arterial stiffness linked to greater intake of red, processed meat
CHF and Arrhythmias
Chronic Adverse Effects From Anti-PD-1 Immunotherapies Common
About 43 percent of patients who receive anti-PD1 therapy for advanced melanoma have chronic immune-related adverse effects
Mortality Lower With PDE5i Treatment in Men With Stable CAD
Mortality risk lower with PDE5i treatment versus alprostadil treatment; similar links seen for MI, heart failure, CV mortality risks
MPR Weekly Dose Podcast 74
Back to regular programming this week with a summary of the top news, which includes updated travel guidance; Six month efficacy data for the Moderna and Pfizer-BioNTech vaccines; Vial doses increased for Moderna; A new ADHD drug is approved; And the FDA has issued a safety communication regarding lamotrigine.
Medicare Claims Database Useful for Detecting Arrhythmogenic Risk of QT-Prolonging Drugs
Study authors evaluated whether using an observational study that includes Medicare claims data could detect the proarrhythmic risk of medications known to prolong the QT interval.
Ozempic Injection 1mg Now Available as a Single Monthly Pen
Anavip contains venom-specific F(ab’)2 fragments of immunoglobulin G that bind and neutralize venom toxins.
FDA: Risk of Arrhythmias With Lamotrigine in Patients With Heart Disease
Lamotrigine is indicated as monotherapy or adjunctive therapy for epilepsy and for use as maintenance treatment in patients with bipolar I disorder.
FDA Approves Device That May Offer Alternative to Open-Heart Surgery
Primary effectiveness of no additional surgical or interventional procedures related to the device and acceptable heart blood flow function at 6 months, was achieved by 89.2%.
FDA: Abuse/Misuse of OTC Nasal Decongestant Can Lead to Major Health Complications
Since January 1, 2000, there have been 460 documented cases of propylhexedrine abuse or misuse reported to US poison control centers.
SGLT2 Inhibitor Use Linked to Reduced Risk of Atrial Arrhythmias in T2DM Patients
This meta-analysis aimed to determine the association between SGLT2i use and arrhythmias in patients with T2DM or HF.
